Abstract
The PACIFIC trial demonstrated the survival benefit of durvalumab as consolidation therapy in patients with unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (cCRT). However, it is necessary to assess the effectiveness of durvalumab consolidation using real-world data.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
